Novo Nordisk A/S (NVO) Stock: Surge as Sogroya Wins Key EU Recommendation for Children

TLDR Sogroya earns EU panel backing for children with idiopathic short stature treatment. Novo Nordisk stock rises as Sogroya clears an important European regulatory hurdle. REAL8 data showed weekly Sogroya matched daily growth hormone therapy at 52 weeks. EU regulators will now review broader approval across three child indications. Sogroya could become the EU’s first [...]

The post Novo Nordisk A/S (NVO) Stock: Surge as Sogroya Wins Key EU Recommendation for Children appeared first on Blockonomi.